Skip to content

The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age

The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01306006
Acronym
MVEPI
Enrollment
3500
Registered
2011-03-01
Start date
2011-02-01
Completion date
2017-12-02
Last updated
2026-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mortality, Vaccines

Keywords

Mortality, Vaccines

Brief summary

The national Expanded Programme on Immunization (EPI) in Guinea-Bissau focuses its efforts exclusively on children below 12 months of age; children who have reached 12 months of age are no longer entitled to vaccines through the EPI program. This has affected the measles vaccination coverage, approx. 30% of the children in the rural area do not receive measles vaccine (MV). Studies from the Bandim Health Project (BHP) have shown that MV has a profound impact on survival, reducing mortality by approximately 50% - far more than can be explained by prevention of measles deaths. Hence, MV seems to have non-specific beneficial effects on survival, and the current policy may have important consequences for overall child mortality. To test the implications of the current policy of only vaccinating children below 12 months of age, the investigators will conduct a cluster randomized trial, in which children will receive their vaccines according to the current national EPI policy (National policy) or receive MV regardless of age and whether some doses of MV may be lost (MV-for-all policy). The investigators hypothesise that among children enrolled after 12 months of age, mortality is 50% lower in children randomised to receive MV compared with children randomised to follow the national policy and not receive MV.

Interventions

BIOLOGICALProviding measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine

Normal measles vaccines licensed for distribution through the national EPI program

Sponsors

Bandim Health Project
Lead SponsorOTHER
Institudo Nacional de Saude Publica INASA
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
9 Months to 35 Months
Healthy volunteers
Yes

Inclusion criteria

* Age 9-35 months, not yet received routine measles vaccination, resident in study area

Exclusion criteria

* To ill to be vaccinated (according to local practice)

Design outcomes

Primary

MeasureTime frame
Mortality

Secondary

MeasureTime frame
Hospital morbidity

Countries

Guinea-Bissau

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026